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Abstract
Purpose Dihydroartemisinin-piperaquine (DP) is a fixed-
dose artemisinin-based combination treatment. Field
pharmacokinetic studies would be simplified and facili-
tated by being able to use small volume capillary assays
rather than venous blood. The aim of this study was to
describe the relationship between piperaquine concen-
trations measured in capillary blood, venous blood and
venous plasma.
Methods Samples of plasma, whole blood obtained by
venesection and capillary blood were taken simulta-
neously from patients with uncomplicated Plasmodium
falciparum malaria treated with DP between 0 and 9 weeks
after treatment. Piperaquine concentrations in venous and
capillary samples were measured using solid phase
extraction and analysis by liquid chromatography with
ultraviolet detection.
Results A total of 161 sets of the three measures were
obtained from 54 patients. Piperaquine concentrations in
the venous blood samples were approximately twofold
higher and those in the capillary blood samples were
threefold higher than the corresponding venous plasma
concentrations. Capillary blood piperaquine concentra-
tions were approximately 1.7-fold higher than venous
blood concentrations, and this difference also increased
with time.
Conclusion Differences in whole blood and plasma levels
of piperaquine suggest compartmentalisation of the drug
within blood cells, as also occurs with the structurally
related quinoline chloroquine. The relationship between
piperaquine concentrations in the venous plasma, venous
blood and capillary blood is variable and unpredictable at
low concentrations. However, within the range of concen-
trations usually present in patients between 3 and 21 days
after treatment with currently recommended doses, the
relationship between capillary and venous whole blood is
predictable; consequently, capillary blood sampling can be
used in field assessments.
Keywords Artemisinin combination therapy.Capillary
blood.Malaria.Piperaquine
Background
The measurement of drug levels is a vital part of any
comprehensive assessment of antimalarial drug efficacy.
Defining the pharmacokinetic properties of the antimalarial
drugs has provided a basis for optimising dosing regimens
and has explained why intrinsically efficacious antimalarial
drugs do not always work. Dihydroartemisinin-piperaquine
(DP) is one of the leading fixed-dose artemisinin-based
combination treatments (ACTs), and has recently been
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Dihydroartemisinin (DHA) is a rapidly eliminated artemi-
sinin derivative and the active metabolite of artesunate,
artemether and artemotil. It has an elimination half-life of
approximately 30–80 min [11, 31, 32]. Piperaquine is a
bisquinoline compound, structurally related to chloroquine
but efficacious against chloroquine-resistant parasites.
Although the drug is more than 40 years old and was used
extensively in China between 1978 and 1992, estimates of
the pharmacokinetic parameters of piperaquine have been
published only in the last 5 years. Like chloroquine,
piperaquine is extensively distributed in tissues and slowly
eliminated. Terminal elimination half-life (t½) estimates
produced by different laboratories have varied between 11
and >60 days [13, 14, 22, 28–30] with studies longer
sampling duration and employing more sensitive assays
giving longer estimates. The oral bioavailability of piper-
aquine has been shown to be increased by co-administration
with fat, which could account for some of the observed
inter-individual variation in pharmacokinetic profiles [23],
although a more recent evaluation of piperaquine pharma-
cokinetics in Vietnamese volunteers found moderately wide
variability in total drug exposure (AUC, area under the
plasma concentration–time curve) which was not related to
concomitant food intake [10]. Studies to date have used
plasma drug assays, although results of whole blood assays
at a single time point have also been reported. In two
separate clinical trials in Laos [18] and Myanmar [25],
piperaquine levels were measured from single samples
taken on day 7 after treatment, as measurements at this time
point provide a useful surrogate of in-vivo drug exposure
[33]. Venous plasma levels were measured in the study in
Laos and whole blood levels (taken onto filter paper) were
analysed in the Myanmar study. The mean [95% confidence
limit (95% CI)] day 7 plasma piperaquine concentration in
the Laos study was 31.8 (28.8–34.8) ng/ml (n=104),
whereas in the Myanmar study, the mean capillary whole
blood value was 72 ng/ml [median (interquartile range) 62
(50–82) ng/ml] (n=156). Thus, concentrations assessed
from capillary whole blood were approximately double
those measured in plasma at the same time point.
The requirements for multiple venepunctures and a cold
chain to transport samples to an analytical laboratory are
major impediments in conducting community-based studies
of antimalarial drugs that incorporate the measurement of
drug concentrations. Assays have been adapted to the field
with the development of sensitive methods capable of
measuring concentrations in very small volume capillary
blood samples, often taken onto filter paper, and by the use
of sparse sampling schedules coupled with non-linear
mixed-effects modelling to generate pharmacokinetic esti-
mates and investigate sources of variation [24].
The principal aim ofthis studywas to compare piperaquine
concentrationsinsamplesofvenousplasmaandvenouswhole
blood with those in capillarywholeblood taken simultaneous-
ly and to determine the relationship between them.
Study design and methods
Study site and population
This was part of a detailed pharmacokinetic study nested
into two larger randomised trials of the efficacy and safety
of DP which have been reported previously [1, 2, 30]. It
took place in clinics of the Shoklo Malaria Research Unit
along the Thai-Myanmar border.
Karen or Burmese patients, aged >2 years, with
symptomatic uncomplicated falciparum infection, rando-
mised to treatment with DP and to the nested pharmacoki-
netic study, were eligible for inclusion. The study was
explained to patients in their own language, and written
consent was obtained (thumbprint if patients were unable to
read or write).
DP dosing regimen
Treatment was directly observed. The total dose was 7 mg/
kg body weight of DHA and 55 mg/kg piperaquine
(Artekin Holley Pharmaceutical Co, Guangzhou, China)
split into four doses at 0, 8, 24 h and 48 h, respectively, or
three doses at 0, 24 and 48 h, respectively.
Sampling
A maximum of four sets of post-treatment samples was
collected from each patient. These were selected randomly
from the following time windows after the first dose of DP:
0–4, 8–12, 24–48, 48–52 h (three-dose arm) or 4–8, 12–24,
28–48, 52–72 h (four-dose arm), and 7, 14, 21, 28, 35, 42,
49, 56 or 63 days (both groups). From the 4.5-ml blood
sample taken by venesection, 1.5 ml was transferred to a
cryo tube, and the remainder was transferred into a sodium
heparin tube; this sample was centrifuged for 10 min at
1500 g and the plasma transferred by pipette to a cryo tube
before freezing in liquid nitrogen. Capillary samples were
taken at the same time from a fingerprick into heparinised
capillary tubes. The blood was then transferred to a cryo
tube to be frozen immediately in liquid nitrogen. Samples
were transferred to the main laboratory in batches where
they were stored at −80°C. After all samples were collected,
they were transferred on dry ice to the Pharmacology
Laboratory in the Faculty of Tropical Medicine, Mahidol
University, Bangkok. Piperaquine concentrations were
measured using a high-throughput assay utilising solid
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ultra-violet detection [15–17]. The lower limit of quantifi-
cation (LLOQ) was higher for the blood assays than for the
plasma assay, mainly because of differences in sample
volumes but also because the recovery of piperaquine from
blood is slightly lower than that from plasma. The plasma
assay could accommodate 1 ml while the blood assay only
accommodated 500 µL. A larger volume of blood resulted
in an unacceptably high back-pressure in the SPE step. The
plasma assay used a 1-ml sample, the blood assay used
0.5 ml and the capillary blood assay used 0.1 ml. The
sample volumes and the impact on assay sensitivity are
summarised in Table 1.
Statistical analysis
The relationships between piperaquine concentrations in
the venous plasma and venous blood, venous plasma and
capillary blood and capillary blood and venous blood
were investigated using regression modelling. Since all
concentrations were log-normally distributed, they were
modelled after a logarithmic transformation. The rela-
tionship between the concentrations was modelled as a
power function, and the optimal fractional polynomial
function was found using the ‘fracpoly’ command in
Stata ver. 10 (StataCorp, College Station, TX). The final
model was a random intercept model to account for
multiple measurements per subject and was adjusted for
time since the first dose or log-parasitaemia, if either
improved the model significantly, as assessed by the
Wald test. For example, the relationship between venous
plasma and venous whole blood concentrations was
estimated using the following model structure:
Log Cvenousblood ðÞ ij ¼ b þ FP Log Cvenousplasma ðÞ ij

þ b1x1ij þ b2x2ij þ vi þ eij
where FP(x) is a fractional polynomial α1 x
p1+...+ αm x
pm ;
p1<...<pm are integer or fractional powers; x1 and x2 are
other covariates, such as time from the first dose or log of
parasitaemia on the day of sampling, vi∼N(0,δb) is a subject-
specific residual and eij∼N(0,δ) is a usual residual. Para-
sitaemia at the time of sampling was estimated from the
fitted log-linear decline in parasite densities assuming a first-
order elimination process. For fitting purposes parasitaemia
was assumed to be equal to half of the detection limit for the
first negative slide.
Normal plots of residuals were examined to check the
assumptions of the regression model. Bland–Altman plots
were used to assess differences between predicted and
measured concentrations. The utility of the models was
assessed by examining the relative difference between the
predicted and observed (measured) concentrations on the
original scale; for example: (predicted venous plasma
concentration – measured venous plasma concentration)/
measured venous plasma concentration × 100%.
Ethical approval
Approval for the study was granted by the Faculty of
Tropical Medicine Ethical Committee, Mahidol University,
Bangkok, Thailand and the Oxford Tropical Ethics Com-
mittee (OXTREC), UK.
Results
The study took place between 2003 and 2004. A total of
161 sets of three simultaneous measures from 54 patients
were analysed. The patient characteristics are shown in
Table 2. A median of three (range 1–4) sets of samples
were collected from the same patient. Piperaquine was
detectable in all of the plasma samples but undetectable in
three venous blood samples and 20 capillary blood samples.
The median piperaquine concentrations were 136.1 (range
0–907.4) ng/ml in capillary samples, 83.9 (0–852.5) ng/ml
in venous samples and 36.3 (2.8–345.1) ng/ml in venous
plasma samples. The LLOQ of the assays, coefficients of
Table 1 Assay sensitivity and quality control results
Parameters Venous plasma (n = 486 samples) Venous blood (n = 186 samples) Capillary blood (n = 178 samples)
Control concentration (ng/ml) 20.0 100 613 59.6 400 2000 59.6 400 2000
Mean value 19.6 98.0 636 56.4 409.3 1979 59.3 410.5 2113
SD 1.3 4.1 26 6.5 37.0 110 4.9 14.1 127
RSD (%) 6.7 4.1 4.1 11.6 9.0 5.5 8.3 3.4 6.0
Sample volume (μl) 1000 500 100
LLOQ (ng/ml) 2.5 15 37.33
SD, standard deviation; RSD, relative standard deviation; LLOQ, lower limit of quantification
There were more plasma samples than venous blood and capillary blood samples because not all patients in the larger pharmacokinetic study gave
all types of blood for testing
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Table 1.
Venous blood versus venous plasma
There were three pairs of samples for which piperaquine
was below the limit of detection in venous blood but
detectable in plasma taken at the same time (plasma
concentrations 4.3, 4.8 and 40.0 ng/ml, respectively). For
the other paired concentrations, venous blood concentra-
tions were nearly always higher than venous plasma
concentrations with a median (90% range) ratio of venous
blood concentration to venous plasma concentration of 2.15
(0.91–5.26). This ratio was strongly negatively correlated
with plasma concentration (Spearman’s ρ=−0.578, p<
0.001) and parasitaemia on the day of sampling (Spear-
man’s ρ=−0.417, p<0.001 and positively correlated with
the interval between dosing and sampling (Spearman’s ρ=
0.550, p<0.001). The best model to describe the relation-
ship between venous blood log-concentration and venous
plasma log-concentration was linear and included log-
parasitaemia at the time of sampling (p<0.001) (Table 3).
The fit was considerably worse at low plasma concen-
trations, particularly if the time and parasite covariates were
not included (Fig. 1a). A Bland–Altman plot (Fig. 1b)
shows a small decrease in the difference between observed
and predicted log concentrations [by 0.109 (95% CI 0.033–
0.184 per 1 U)], which corresponds to much larger
differences on the original scale.
Venous plasma versus capillary blood
In 20 pairs of samples piperaquine was undetectable in
capillary blood but detectable in plasma taken at the same
time [median plasma concentrations 4.8 (90% range 2.9–
40.0) ng/ml]. Median capillary blood levels at which
piperaquine was detectable in both venous plasma and
capillary blood samples were 3.5-fold (90% range 1.7–7.4)
higher than those measured in plasma. This ratio was not
correlated with plasma concentration, the time of sampling
or parasitaemia on the day of sampling. The best model to
describe the relationship between log plasma concentration
Table 2 Characteristics of 97 patients with uncomplicated falciparum
malaria treated with dihydroartemisinin-piperaquine (DP) in the
pharmacokinetic study
Patient characteristics Values
Male, n (%) 58 (60)
Age (years) 25 (3–55)
Weight (kg) 48 (12–74)
Haematocrit on enrolment (%) 39 (20–52)
Three-dose DP treatment, n (%) 47 (49)
Parasitaemia/μl, geometric mean 10,887 (83–223,872)
Piperaquine total dose, mg/kg 53.3 (40–74)
The results are expressed as the median value with the range given in
parenthesis unless stated otherwise
Parameters Transformation Coefficient 95% Confidence interval p value
Log(venous blood concentration) = f(venous plasma concentration)
Plasma concentration Log(x) 0.754 0.697–0.811 0.000
Parasitaemia Log10(x+1) −0.125 −0.167 to −0.082 0.001
Constant (α) 1.752 1.538–1.966 0.000
σb 0.210 0.138–0.319 0.005
a
σ 0.358 0.312–0.410
r ¼ s2
b= s2
b þ s2 
0.256 0.109–0.468
Log(venous plasma concentration) = f(capillary blood concentration)
Capillary concentration Log(x) 0.974 0.864–1.084 <0.001
Constant (α) −1.072 −1.637 to −0.506 <0.001
σb 0.294 0.192–0.449 0.002
a
σ 0.456 0.391–0.530
r ¼ s2
b= s2
b þ s2 
0.293 0.125–0.525
Log(venous blood concentration) = f(capillary blood concentration)
Capillary concentration Log(x) 0.920 0.903–0.938 <0.001
Parasitaemia Log10(x+1) −0.112 −0.145 to −0.078 <0.001
Constant (α)0
σb 0.252 0.189–0.338 <0.001
a
σ 0.264 0.228–0.306
r ¼ s2
b= s2
b þ s2 
0.477 0.306–0.653
Table 3 Summary of the
models used to describe the
relationship between the con-
centrations of piperaquine in
venous plasma and those in
capillary and venous
whole blood
σb, between subject variation;
σ, residual variation
aLikelihood ratio test of σb=0
708 Eur J Clin Pharmacol (2010) 66:705–712and log capillary concentration was linear without cova-
riates (Table 3). Predicted (from piperaquine capillary
concentrations) versus measured piperaquine venous plas-
ma concentrations are shown in Fig. 2a. The Bland–Altman
plot (Fig. 2b) shows a decrease in the difference between
observed and predicted log concentrations [by 0.218 (90%
range 0.113–0.323) per 1 U], which corresponds to much
larger differences on the original scale.
Capillary blood versus venous blood
Piperaquine was undetectable in 20 capillary blood sam-
ples; of these, piperaquine was also undetectable in three
corresponding samples of venous blood. Of the remaining
17 samples, the median venous concentration (90% range)
was 20.55 (12.32–68.65) ng/ml.
On average, capillary drug levels were 1.66-fold higher
(90% range 0.92–3.03) than the levels measured in
corresponding venous blood samples. This ratio was strongly
negatively correlated with the interval between dosing and
sampling (Spearman’s ρ=−0.45, p<0.001) and positively
correlated with parasitaemia on the day of sampling (Spear-
man’s ρ=0.45, p<0.001). The best model to describe the
relationship between venous log-concentration and capillary
log-concentration was linear and included log-parasitaemia
at the time of sampling (p<0.001) (Table 3). The Bland–
Altman plot (Fig. 3) shows a small decrease in the difference
between observed and predicted log concentrations [by
0.128 (90% range 0.052–0.204) per 1 U] which would be
0.175 (90% range 0.92–0.258) if parasitaemia was not
included in the model. Differences on the original scale are
larger, but the majority (89%, 125/141) of measures remain
within 50%. Overall, 58% (82/141) of predicted venous
blood concentrations (from capillary concentrations) were
within 20% of the measured venous concentrations, while
70% (99/141) were within 30%. The discrepancies were
Fig. 1 Assessment of the relationship between venous blood and
venous plasma concentrations of piperaquine. Model was adjusted
for parasitaemia at the time of sampling. a Predicted versus
measured venous blood concentrations. Natural log scale. b Bland–
Altman plot for measured and predicted venous blood concentration
Fig. 2 Assessment of the relationship between venous plasma and
capillary blood concentrations of piperaquine. a Predicted versus
measured venous plasma concentrations. Natural log scale. b Bland–
Altman plot for measured and predicted venous plasma concentration
Eur J Clin Pharmacol (2010) 66:705–712 709higher for low concentrations, with only 41% (7/17) of
predicted venous blood concentrations remaining within the
20 or 30% range for venous concentrations <30 ng/ml. For
concentrations >30 ng/ml, these proportions were 60% (75/
124) and 74% (92/124), respectively. These values remained
the same if the cut-off was taken as 40 or 50 ng/ml. Nearly
all (93%, or 96/103) capillary blood concentrations taken
between 24 h after the first dose and before or on day 21
were >30 ng/ml. From day 28 onwards, the majority (77%)
of concentrations were <30 ng/ml. After day 3, when
parasitaemia had cleared, the relationship between venous
piperaquine concentrations and capillary concentrations
became simpler: venous concentration = (capillary concentra-
tion)
0.9. Among samples taken after day 3 and before day 28,
70% (42/60) of the predicted venous blood concentrations
were within 30% of the measured venous blood concen-
trations, and 62% (37/60) of predictions were within 20%;
consequently, the observed versus expected agreement was
good in this time interval.
Figure 4 compares the predictive utilities of all models.
Discussion
In most pharmacological assessments drugs are measured in
plasma. Many antimalarial drugs are eliminated slowly
from the body, and the measurement of drug concentrations
in small volumes of whole blood taken from a finger prick
sample is more convenient and more acceptable in young
children. This allows community-based assessments, even
in very remote settings, providing essential information on
drug efficacy, adherence and toxicity. The new ACT
dihydroartemisinin-piperaquine is likely to have a major
role in antimalarial treatment, so the development of field-
based tools for its assessment is important. The results of
this study show that measurements of piperaquine in
venous plasma, venous or capillary blood are not readily
interchangeable across the whole range of concentrations
encountered in patients with current dosing. Piperaquine
concentrations were highest in capillary whole blood,
followed in decreasing concentrations by venous whole
blood and venous plasma. The higher concentrations of
piperaquine detected in whole blood compared to plasma
suggests that piperaquine concentrates within blood cells.
These results are consistent with previous findings that
capillary blood concentrations were approximately double
Fig. 4 Distribution of the relative difference (%) between measured
and predicted values of piperaquine for: a venous blood concentration
predicted from venous plasma concentration, adjusted for para-
sitaemia, b venous blood concentration predicted from venous plasma
concentration, unadjusted for parasitaemia, c venous plasma concen-
tration predicted from capillary blood concentration, d venous blood
concentration predicted from capillary blood concentration, adjusted
for parasitaemia, e venous blood concentration predicted from
capillary blood concentration, unadjusted for parasitaemia. Bound-
aries of the boxes 25th and 75th centiles, line in the box median
Fig. 3 Assessment of the relationship between venous blood and
capillary blood concentrations of piperaquine. Model was adjusted
for parasitaemia at the time of sampling. a Predicted versus
measured venous blood concentrations. Natural log scale. b Bland–
Altman plot for measured and predicted venous blood concentration
710 Eur J Clin Pharmacol (2010) 66:705–712those measured in plasma at day 7 [18, 25]. Studies of
chloroquine pharmacokinetics have reported concentrations
in erythrocytes that are usually two to fivefold higher than
those in plasma. Chloroquine is also concentrated markedly
in leukocytes and platelets [3]. This underlies the differ-
ences between plasma and serum concentrations and
contributes to the variability in plasma concentrations.
The duration and force of centrifugation has been shown
to influence the concentrations of chloroquine and its
metabolite desethylchloroquine in plasma, with concentra-
tions of both drugs decreasing as the centrifugal force
increases until relatively stable levels are reached at 500 g
(due to variable removal of white cells and platelets). The
measurement of whole blood concentrations avoids this
potential confounder [21] and is now the generally accepted
method for measuring chloroquine in therapeutic assess-
ments. In the seminal study of Gustafasson et al. [9]o f1 1
healthy volunteers in whom chloroquine concentrations
were measured in plasma and erythrocytes for 3–8 weeks
after dosage, the disposition of chloroquine in erythrocytes
paralleled that in plasma.
There is a consistent increase in platelet count (often
doubling) and haematocrit (circa 10%) in patients recover-
ing from acute uncomplicated malaria [20]. Neutrophil
counts also tend to increase. In acute malaria, patients may
be dehydrated and haemoconcentrated when they present,
and there are reduced concentrations of albumin (which
binds acidic drugs) and marked increases in the concen-
trations of the acute phase protein α 1-acid glycoprotein
(binds basic drugs). In addition, capillary blood samples are
affected by factors affecting peripheral perfusion and tissue
fluid concentrations as they contain a variable admixture of
interstitial fluid. In cases of acute malaria, patients are
usually febrile and vasodilated, whereas following recovery
there may be peripheral vasoconstriction, leading to greater
tissue fluid admixture in capillary samples. Previous studies
in patients and volunteers without malaria have revealed
that the haematocrit and leucocyte levels tend to be higher
in capillary blood samples than in venous blood samples,
while platelet numbers tend to be similar or lower [5–7,27,
34]. Haematocrit measurements have also been observed to
be more variable on repeated capillary sampling than on
repeated venous sampling. This could partially explain the
inter-individual variability of the relationship shown here.
For certain drugs, such as neuroleptics, the red cell
concentrations have been reported to correlate better with
therapeutic effects or dose than plasma concentrations [4, 8,
26].
Hinderling [12] has argued that for drugs with a Kb/p
(blood to plasma concentration ratio) >2.0, measuring
concentrations in whole blood or erythrocytes rather than in
plasma lowers the LLOQ. The increased sensitivity permits
the kinetics of the drug to be followed up for at least one
additional half-life. In our study, the LLOQ was higher in the
blood assays than the plasma assay, mainly because of
differences in sample volumes but also because the recovery
of piperaquine from blood is slightly lower than that from
plasma. The plasma assay used a 1-ml sample to obtain a
LLOQ of 2.5 ng/ml, while the capillary blood assay used a
0.1-ml sample to obtain a LLOQ of 37 ng/ml.
The model for the relationship between piperaquine
concentrations measured in venous and capillary blood
adjusted for parasitaemia showed the least amount of
variability between observed and predicted concentrations,
but this may be attributable to the large proportion of
undetectable results at the lower end of the concentration
range for the capillary measurements.
The relationship between piperaquine concentrations in
plasma, venous blood and capillary bloods is variable and
not predictable at low concentrations. Further studies are
recommended to characterise the compartmentalisation in
blood cells, to compare estimates of piperaquine pharma-
cokinetic parameters in plasma and whole blood and to
provide information on the optimum samples for field
studies in terms of drug measurement. A simple approach
for most field studies is to take a single measurement of
drug concentration on day 7. At this point, parasitaemia has
almost invariably cleared, and a good approximation of the
venous concentration is (capillary concentration)
0.9. Thus,
despite certain limitations, the capillary blood piperaquine
measurement could prove to be useful in field assessment
studies of therapeutic efficacy and adherence.
Acknowledgments We would like to thank all the patients of
SMRU who provided samples for the study and all colleagues
involved in taking, processing, transporting and analysing specimens.
This work was part of the Wellcome Trust-Mahidol University,
Oxford Tropical Medicine Research Programme, funded by the
Wellcome Trust.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Ashley EA, Krudsood S, Phaiphun L, Srivilairit S, McGready R,
Leowattana W, Hutagalung R, Wilairatana P, Brockman A,
Looareesuwan S, Nosten F, White NJ (2004) Randomized,
controlled dose-optimization studies of dihydroartemisinin-
piperaquine for the treatment of uncomplicated multidrug-
resistant falciparum malaria in Thailand. J Infect Dis 190
(10):1773–1782, Erratum in: J Infect Dis. 2005;191(7):1204
2. Ashley EA, McGready R, Hutagalung R, Phaiphun L, Slight T,
Proux S, Thwai KL, Barends M, Looareesuwan S, White NJ,
Nosten F (2005) A randomized, controlled study of a simple,
once-daily regimen of dihydroartemisinin-piperaquine for the
Eur J Clin Pharmacol (2010) 66:705–712 711treatment of uncomplicated, multidrug-resistant falciparum malar-
ia. Clin Infect Dis 41(4):425–432
3. Bergqvist Y, Domeij-Nyberg B (1983) Distribution of chloro-
quine and its metabolite desethyl-chloroquine in human blood
cells and its implication for the quantitative determination of
these compounds in serum and plasma. J Chromatogr 272
(1):137–148
4. Casper R, Garver DL, Dekirmenjian H, Chang S, Davis J (1980)
Phenothiazine levels in plasma and red blood cells. Arch Gen
Psychiatry 37:301–305
5. Daae LN, Halvorsen S, Mathisen PM, Mironska K (1988) A
comparison between haematological parameters in 'capillary'
and venous blood from healthy adults. Scand J Clin Lab Invest
48(7):723–726, Erratum in: Scand J Clin Lab Invest 1989;49
(3):305
6. Daae LN, Hallerud M, Halvorsen S (1991) A comparison between
haematological parameters in 'capillary' and venous blood samples
from hospitalized children aged 3 months to 14 years. Scand J
Clin Lab Invest 51(7):651–654
7. Feusner JH, Behrens JA, Detter JC, Cullen TC (1979) Platelet
counts in capillary blood. Am J Clin Pathol 72(3):410–414
8. Garver DL, Dekirmenjian H, Davis JM, Casper R, Ericksen S
(1977) Neuroleptic drug levels and therapeutic response: prelim-
inary observations with red blood cells - bound butaperazine. Am
J Psychiatry 134:304–307
9. Gustafasson LL, Walker O, Alván G, Beermann B, Estevez F,
Gleisner L, Lindström B, Sjöqvist F (1983) Disposition of
chloroquine in man after single intravenous and oral doses. Br J
Clin Pharmacol 15(4):471–479
10. Hai TN, Hietala SF, Van Huong N, Ashton M (2008) The
influence of food on the pharmacokinetics of piperaquine in
healthy Vietnamese volunteers. Acta Trop 107(2):145–149
11. Hien TT, Davis TM, Chuong LV, Ilett KF, Sinh DX, Phu NH,
Agus C, Chiswell GM, White NJ, Farrar J (2004) Comparative
pharmacokinetics of intramuscular artesunate and artemether in
patients with severe falciparum malaria. Antimicrob Agents
Chemother 48(11):4234–4239, Erratum in: Antimicrob Agents
Chemother. 2005;49(2):871
12. Hinderling PH (1997) Red blood cells: a neglected compartment
in pharmacokinetics and pharmacodynamics. Pharmacol Rev 49
(3):279–295
13. Hung TY, Davis TM, Ilett KF (2003) Measurement of piperaquine
in plasma by liquid chromatography with ultraviolet absorbance
detection. J Chromatogr B Analyt Technol Biomed Life Sci 791
(1–2):93–101
14. Hung TY, Davis TM, Ilett KF, Karunajeewa H, Hewitt S, Denis MB,
Lim C, Socheat D (2004) Population pharmacokinetics of piper-
aquineinadultsandchildrenwithuncomplicatedfalciparumorvivax
malaria. Br J Clin Pharmacol 57(3):253–262
15. Lindegardh N, Ashton M, Bergqvist Y (2003) Automated solid-
phase extraction method for the determination of piperaquine in
whole blood by rapid liquid chromatography. Ther Drug Monit 25
(5):544–551
16. Lindegardh N, Ashton M, Bergqvist Y (2003) Automated solid-
phase extraction method for the determination of piperaquine in
plasma by peak compression liquid chromatography. J Chroma-
togr Sci 41(1):44–49
17. Lindegardh N, White NJ, Day NP (2005) High throughput assay
for the determination of piperaquine in plasma. J Pharm Biomed
Anal 39(3–4):601–605
18. Mayxay M, Thongpraseuth V, Khanthavong M, Lindegardh N,
Barends M, Keola S, Pongvongsa T, Phompida S, Phetsouvanh R,
Stepniewska K, White NJ, Newton PN (2006) An open, randomized
comparison of artesunate plus mefloquine vs. dihydroartemisinin-
piperaquine for the treatment of uncomplicated Plasmodium falci-
parum malaria in the Lao People's Democratic Republic (Laos).
Trop Med Int Health 11(8):1157–1165
19. Orjih AU (1987) Increased accumulation of chloroquine and
desethylchloroquine in homozygous sickle cells. Bull WHO 65
(1):51–55
20. Price RN, Simpson JA, Nosten F, Luxemburger C, Hkirjaroen L,
ter Kuile F, Chongsuphajaisiddhi T, White NJ (2001) Factors
contributing to anemia after uncomplicated falciparum malaria.
Am J Trop Med Hyg 65(5):614–622
21. Rombo L, Ericsson O, Alvan G, Lindstrom B, Gustafsson LL,
Sjoqvist F (1985) Chloroquine and desethylchloroquine in plasma,
serum, and whole blood: problems in assay and handling of
samples. Ther Drug Monit 7(2):211–215
22. Roshammar D, Hai TN, Friberg Hietala S, Van Huong N, Ashton
M (2006) Pharmacokinetics of piperaquine after repeated oral
administration of the antimalarial combination CV8 in 12 healthy
male subjects. Eur J Clin Pharmacol 62(5):335–341
23. Sim IK, Davis TM, Ilett KF (2005) Effects of a high-fat meal on
the relative oral bioavailability of piperaquine. Antimicrob Agents
Chemother 49(6):2407–2411
24. Simpson JA, Aarons L, White NJ (2001) How can we do
pharmacokinetic studies in the tropics? Trans R Soc Trop Med
Hyg 95:347–351
25. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M,
LindegardhN,SingtorojT,AshleyE, Lwin S, StepniewskaK,White
NJ (2006) Efficacy and effectiveness of dihydroartemisinin-
piperaquine versus artesunate-mefloquine in falciparum malaria: an
open-label randomized comparison. Lancet 367(9528):2075–2085
26. Svensson C, Nyberg G, Axelsson R, Mårtensson E (1986)
Concentrations of thioridazine and thioridazine metabolites in
erythrocytes. Psychopharmacology 89:291–293
27. Tai DY, Chan KW, Chee YC, Mak KH (1995) Comparison of
platelet counts in simultaneous venous and capillary blood
samples using an automated platelet analyser. Singapore Med J
36(3):263–266
28. Tarning J, Bergqvist Y, Day NP, Bergquist J, Arvidsson B, White
NJ, Ashton M, Lindegardh N (2006) Characterization of human
urinary metabolites of the antimalarial piperaquine. Drug Metab
Dispos 34(12):2011–2019
29. Tarning J, Lindegardh N, Annerberg A, Singtoroj T, Day NP,
Ashton M, White NJ (2005) Pitfalls in estimating piperaquine
elimination. Antimicrob Agents Chemother 49(12):5127–5128
30. Tarning J, Ashley EA, Lindegardh N, Stepniewska K, Phaiphun L,
Day NP, McGready R, Ashton M, Nosten F, White NJ (2008)
Population pharmacokinetics of piperaquine after two different
treatment regimens with dihydroartemisinin-piperaquine in patients
with acute uncomplicated Plasmodium falciparum malaria in
Thailand. Antimicrob Agents Chemother 52(3):1052–1061, 2007
31. Teja-Isavadharm P, Watt G, Eamsila C, Jongsakul K, Li Q,
Keeratithakul G, Sirisopana N, Luesutthiviboon L, Brewer TG
(2001) Kyle DE.Comparative pharmacokinetics and effect kinetics
of orally administered artesunate in healthy volunteers and
patients with uncomplicated falciparum malaria. Am J Trop Med
Hyg 65(6):717–721
32. White NJ (1994) Clinical pharmacokinetics and pharmacodynam-
ics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 88
[Suppl 1]:S41–S43
33. White NJ, Stepniewska K, Barnes K, Price RN, Simpson J (2008)
Simplified antimalarial therapeutic monitoring: using the day-7
drug level? Trends Parasitol 24:159–163
34. YangZW,YangSH,ChenL,QuJ,ZhuJ,TangZ(2001)Comparison
of blood counts in venous, fingertip and arterial blood and their
measurement variation. Clin Lab Haematol 23(3):155–159
712 Eur J Clin Pharmacol (2010) 66:705–712